Background Incorporation of a taxane while adjuvant treatment for early breasts

Background Incorporation of a taxane while adjuvant treatment for early breasts cancer offers prospect of further improvement of anthracycline-based treatment. FEC for eight cycles (n=1265) or epirubicin (100 mg/m2 at 3-every week intervals) for four cycles accompanied by CMF (cyclophosphamide 600 mg/m2, methotrexate 40 mg/m2, and fluorouracil 600 mg/m2 at 4-every week intervals) for four… Continue reading Background Incorporation of a taxane while adjuvant treatment for early breasts